Patents by Inventor Mohamed Amine BAYAR

Mohamed Amine BAYAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of the expression of specific genes for the prognosis of patients with triple negative breast cancer
    Patent number: 11466327
    Abstract: The present invention relates to the use of the value of the expression of at least one gene selected from the group comprising: GBP 1 gene, HLF gene, CXCL13 gene and SULT1E1 gene, for the estimation of prognosis of distant relapse-free survival or overall survival of a patient with triple negative breast cancer (TNBC) having received a neoadjuvant chemotherapy (NACT).
    Type: Grant
    Filed: July 3, 2017
    Date of Patent: October 11, 2022
    Assignees: ISTITUTO EUROPEO DI ONCOLOGIA (IEO), INSTITUT GUSTAVE ROUSSY
    Inventors: Michiels Stefan, Mohamed Amine Bayar, Fabrice Andre, Carmen Criscitiello, Giuseppe Curigliano
  • USE OF THE EXPRESSION OF SPECIFIC GENES FOR THE PROGNOSIS OF PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER
    Publication number: 20200071766
    Abstract: The present invention relates to the use of the value of the expression of at least one gene selected from the group comprising: GBP 1 gene, HLF gene, CXCL13 gene and SULT1E1 gene, for the estimation of prognosis of distant relapse-free survival or overall survival of a patient with triple negative breast cancer (TNBC) having received a neoadjuvant chemotherapy (NACT).
    Type: Application
    Filed: July 3, 2017
    Publication date: March 5, 2020
    Inventors: Michiels STEFAN, Mohamed Amine BAYAR, Fabrice ANDRE, Carmen CRISCITIELLO, Giuseppe CURIGLIANO